ERK2 (MAPK1) Mouse Monoclonal Capture Antibody [Clone ID: OTI6F8]

SKU TA600063

MAPK1 mouse monoclonal capture antibody, validated for ELISA and Luminex assays

Product Data

• Clone Name: OTI6F8
• Application: ELISA, LMNX
• Recommended Dilution: 1:100 - 1:1000
• Reactivity: Human, Mouse, Rat
• Antibody Host: Mouse
• Isotype: IgG1
• Clonality: Monoclonal
• Immunogen: Full length human recombinant protein of human MAPK1 (NM_138957) produced in HEK293T cell.
• Buffer: Stored in PBS (pH 7.4) containing 0.05% sodium azide and up to 5% trehalose
• Concentration: 0.5 mg/ml
• Conjugation: Unconjugated
• Storage: Store at -20°C.; Avoid repeat freeze/thaw cycles.
• Stability: Stable for 12 months from date of receipt.
• Shipping: Blue Ice
• Gene Name: mitogen-activated protein kinase 1
• Database Link:
  NP_620407
  P28482
• Synonyms: ERK; ERK-2; ERK2; ERT1; MAPK2; NS13; p38; p40; p41; p41mapk; p42-MAPK; P42MAPK; PRKM1; PRKM2
• Matched ELISA Pair: TA700062, TA700064

Reference Data

• Protein Families: Druggable Genome, Protein Kinase
• Protein Pathways: Acute myeloid leukemia, Adherens junction, Alzheimer's disease, Axon guidance, B cell receptor signaling pathway, Bladder cancer, Chemokine signaling pathway, Chronic myeloid leukemia, Colorectal cancer, Dorso-ventral axis formation, Endometrial cancer, ErbB signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, Gap junction, Glioma, GnRH signaling pathway, Insulin signaling pathway, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, mTOR signaling pathway, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, NOD-like receptor signaling pathway, Non-small cell lung cancer, Oocyte meiosis, Pancreatic cancer, Pathways in cancer, Prion diseases, Progesterone-mediated oocyte maturation, Prostate cancer, Regulation of actin cytoskeleton, Renal cell carcinoma, T cell receptor signaling pathway, TGF-beta signaling pathway, Thyroid cancer, Toll-like receptor signaling pathway, Type II diabetes mellitus, Vascular smooth muscle contraction, VEGF signaling pathway